Familial Mediterranean Fever, Kenya, Colchicine discussed on NEJM This Week - Audio Summaries

Automatic TRANSCRIPT

Canna kenya mab for the treatment of auto inflammatory recurrent fever syndromes by fabrizio debenham deti from the auspey dollar pediatric obam beano jesu rome italy in this trial patients with genetically confirmed colchicine resistant familial mediterranean fever mcgowan eight kindness deficiency or tumor necrosis factor receptor associated periodic syndrome craps were randomly assigned at the time of flair to receive one hundred fifty milligrams of cana kenya mab subcutaneous ly or placebo every four weeks at week sixteen significantly more patients receiving catechin kenya mab had a complete response than those receiving placebo sixty one percent versus six percent of patients with culture seen resistant familial mediterranean fever thirty five percent versus six percent of those with mcgowan eight deficiency and forty five percent versus eight percent of those with traps the inclusion of patients whose dose was increased to three hundred milligrams every four weeks yielded a complete response in seventy one percent of those with culture seen resistant familial mediterranean fever fifty seven percent of those with mcgowan eight kinds deficiency and seventy three percent of those with traps after week sixteen and extended dosing regimen every eight weeks maintained disease control in forty six percent of patients with culture seen resistant familial mediterranean fever twenty three percent of those with mcgowan eight kinds deficiency and fifty three percent of those with traps in all three cohorts infections were more numerous in the catechin kenya map group in this trial catechin you mab was affective in controlling and preventing flares in patients with culture seen resistant familial mediterranean fever mcgowan eight kinds deficiency and traps.

Coming up next